
Even though Genmab's superseller, Darzalex, brought in USD 2.8bn in the first half of 2021 against USD 1.8bn from the same period last year – thereby playing a role in driving the recent guidance upgrade – the Danish biotech group is still able to note some less fortunate news for the period.
The company's second-quarter interim report shows that Genmab's royalty payments from Janssen Pharmaceuticals, which sells Darzalex on behalf of Genmab, only increased by 43 percent despite a 52 percent growth in sales during the same period.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
Fruergaard leveraging experience from Danish partnerships in key roles in Brussels
Experiences from Danish climate partnerships are among the tools that can be leveraged when Novo Nordisk CEO Lars Fruergaard begins stepping up efforts in the life science sector’s central organs in Brussels. ”I’ve been fired up by the intimacy and shared vision we could see in Denmark,” he tells MedWatch.